---
schema_version: "secwatch.filing_event.v1"
accession: "0001725160-26-000020"
form_type: "8-K"
ticker: "ZNTL"
cik: "0001725160"
company_name: "Zentalis Pharmaceuticals, Inc."
filed_at: "2026-04-17T23:59:59+00:00"
generated_at: "2026-05-15T05:32:13.488387+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Zentalis presents preclinical azenosertib data in TNBC; real-world ovarian cancer outcomes shown

## Summary
- Azenosertib + enfortumab vedotin induced 87.5% complete responses in ADC-resistant TNBC PDX model; 5 of 8 mice had no progression after treatment stop.
- Median PFS not reached for azenosertib+EV vs. 22 days for EV alone (HR=0.14, p<0.0001) in TOP1i-ADC-resistant model.
- Real-world data: Cyclin E1-positive ovarian cancer patients had shorter time to next treatment (13.2–14.9 months) vs. Cyclin E1-negative (19.5 months), p=0.002.
- Azenosertib monotherapy showed 42–99% tumor growth inhibition across 12 TNBC xenograft models.
- Data presented at AACR 2026; company plans to explore azenosertib combinations post-ADC in TNBC.

## SEC filing metadata
- accession: 0001725160-26-000020
- form_type: 8-K
- ticker: ZNTL
- cik: 0001725160
- company_name: Zentalis Pharmaceuticals, Inc.
- filed_at: 2026-04-17T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1725160/000172516026000020/0001725160-26-000020-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1725160/000172516026000020/zntl-20260417.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001725160-26-000020
- JSON: https://secwatch.observer/filing/0001725160-26-000020.json
- Plain text: https://secwatch.observer/filing/0001725160-26-000020.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.